- Language: English
- Published: August 2013
- Published: March 2011
- 29 pages
This analysis highlights that schizophrenia is and will remain an important health burden in the seven major healthcare markets. However, the number of schizophrenia patients will remain fairly constant over the next 10 years. The highest increase in the number of cases will be in the US, with the majority of the seven major markets posting minor increases.
Features and benefits
- Gain insight to market potential, including a robust 10 year epidemiology forecast of schizophrenia prevalent cases
- Understand the key epidemiologic risk factors associated with schizophrenia
- In 2009, in the seven major healthcare markets, there were about four and half million men and women with schizophrenia—almost half of these were in the US. Between 2009 and 2019, the number of schizophrenia prevalent cases will increase marginally in these markets.
- Since the 1950s, when robust epidemiologic studies coupled with improved disease classification and diagnosis criteria, the incidence and prevalence of schizophrenia seem to have remained constant over time even though with small variations due to these diagnostic criteria.
Your key questions answered
- What are the most robust sources for schizophrenia prevalence data?
- How will the patient population change over the next decade in the US, Japan and the five major EU markets (France, Germany, Italy, Spain and the UK)?
- How do changes in population structure and risk factors affec the trend in prevalent schizophrenia cases?
SHOW LESS READ MORE >